Skip to content
First experience of ECAT with Measurement of New Oral Anticoagulation Drugs
8th ECAT International Symposium 2012
Speaker
Titel
Abstract
Presentation
M.P.M. de Maat
First experience of ECAT with Measurement of New Oral Anticoagulation Drugs
Related items
Analytical Information :
4
Minimum citrate tube fill volume for routine coagulation testing
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
2
Acquired protein S deficiency with purpura fulminans presentation in the aftermath of varicella zoster in a child
Dysfibrinogenemia, case study
ECAT Documents :
35
Short-term biological variation of coagulation and fibrinolytic measurands
Thrombus (plural form is Thrombi)
Hypofibrinogenemia
Fibrinogen (FI) and Fibrinogen Assay
Fibrin
Dysfibrinogenemia
Common Pathway of Coagulation
Coagulation Factors
Coagulation Cascade
Clot (Blood Clot)
Antithrombin
Detecting molecular forms of antithrombin by LC-MRM-MS: defining the measurands
Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice?
Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH.
Clotting and Fibrinolysis: an integrated test system
Generation assays in coagulation and fibrinolysis: Principles and possibilities
The results of the workshop on inhibitor testing
A scoring system based on the biological variation
Biological variation of inflammatory and hemostatic markers
Biological variation and analytical quality specifications
Biological variation and quality control
Global haemostasis assays: what will be the future?
Factor VIII inhibitor testing – a way to comparable test results
Laboratory assays for the measurement of Factor VIII and IX
Medical device thrombosis
Is standardisation in coagulation feasible?
Laboratory Guidelines for Antithrombin, Proteins C and S, and APC-Resistance Testing
The use of snake venoms in the coagulation laboratory
Biological variation, quality specifications and Six Sigma
Next-generation antithrombin diagnostics by mass spectrometry
When Haemostasis Assays Mislead
Biological Variation in haemostasis
Method validation for haemostasis assays
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
Guidelines :
2
Recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders, ICSH recommendations
Thrombin generation measurement in haemophilia, SSC recommendation
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Fibrinolytic Pathway
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Quality Issues :
1
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Questions or suggestions?
Clotpedia Support Form
Submit
Success